NASDAQ
IOVA

Iovance Biotherapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Iovance Biotherapeutics Inc Stock Price

Vitals

Today's Low:
$5.94
Today's High:
$6.47
Open Price:
$6.03
52W Low:
$5.28
52W High:
$11.88
Prev. Close:
$6.03
Volume:
3494690

Company Statistics

Market Cap.:
$1.49 billion
Book Value:
2.575
Revenue TTM:
$238000
Operating Margin TTM:
-179988.66%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-39.14%
Return on Equity TTM:
-79.68%

Company Profile

Iovance Biotherapeutics Inc had its IPO on 2010-10-15 under the ticker symbol IOVA.

The company operates in the Healthcare sector and Biotechnology industry. Iovance Biotherapeutics Inc has a staff strength of 503 employees.

Stock update

Shares of Iovance Biotherapeutics Inc opened at $6.03 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $5.94 - $6.47, and closed at $5.96.

This is a -1.16% slip from the previous day's closing price.

A total volume of 3,494,690 shares were traded at the close of the day’s session.

In the last one week, shares of Iovance Biotherapeutics Inc have slipped by -3.09%.

Iovance Biotherapeutics Inc's Key Ratios

Iovance Biotherapeutics Inc has a market cap of $1.49 billion, indicating a price to book ratio of 2.7741 and a price to sales ratio of 0.

In the last 12-months Iovance Biotherapeutics Inc’s revenue was $238000 with a gross profit of $0 and an EBITDA of $-417380000. The EBITDA ratio measures Iovance Biotherapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Iovance Biotherapeutics Inc’s operating margin was -179988.66% while its return on assets stood at -39.14% with a return of equity of -79.68%.

In Q2, Iovance Biotherapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Iovance Biotherapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-2.35 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Iovance Biotherapeutics Inc’s profitability.

Iovance Biotherapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.1868. Its price to sales ratio in the trailing 12-months stood at 0.

Iovance Biotherapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$757.29 million
Total Liabilities
$88.64 million
Operating Cash Flow
$-156779000.00
Capital Expenditure
$9.52 million
Dividend Payout Ratio
0%

Iovance Biotherapeutics Inc ended 2024 with $757.29 million in total assets and $0 in total liabilities. Its intangible assets were valued at $757.29 million while shareholder equity stood at $578.57 million.

Iovance Biotherapeutics Inc ended 2024 with $20.24 million in deferred long-term liabilities, $88.64 million in other current liabilities, 9000.00 in common stock, $-1782236000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $230.01 million and cash and short-term investments were $250.89 million. The company’s total short-term debt was $10,866,000 while long-term debt stood at $1.00 million.

Iovance Biotherapeutics Inc’s total current assets stands at $274.88 million while long-term investments were $0 and short-term investments were $20.88 million. Its net receivables were $33000.00 compared to accounts payable of $31.16 million and inventory worth $9.72 million.

In 2024, Iovance Biotherapeutics Inc's operating cash flow was $-156779000.00 while its capital expenditure stood at $9.52 million.

Comparatively, Iovance Biotherapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$5.96
52-Week High
$11.88
52-Week Low
$5.28
Analyst Target Price
$22.38

Iovance Biotherapeutics Inc stock is currently trading at $5.96 per share. It touched a 52-week high of $11.88 and a 52-week low of $11.88. Analysts tracking the stock have a 12-month average target price of $22.38.

Its 50-day moving average was $6.94 and 200-day moving average was $6.93 The short ratio stood at 6.3 indicating a short percent outstanding of 0%.

Around 32.7% of the company’s stock are held by insiders while 9140.5% are held by institutions.

Frequently Asked Questions About Iovance Biotherapeutics Inc

The stock symbol (also called stock or share ticker) of Iovance Biotherapeutics Inc is IOVA

The IPO of Iovance Biotherapeutics Inc took place on 2010-10-15

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
Adidas AG ADR (ADDYY)
$95.85
1.75
+1.86%
$53.44
-4.02
-7%
$3.36
-0.05
-1.47%
$40.07
-0.13
-0.32%
$11.22
-0.29
-2.52%
$0.61
0
0%
$71.85
-5.23
-6.79%
$16.18
0.44
+2.76%
ICRA Limited (532835)
$5658.25
-69.75
-1.22%
$0.07
-0.01
-15.26%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient’s immune system to eradicate cancer cells. The company’s lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l’Université de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Address

825 Industrial Road, San Carlos, CA, United States, 94070